Target Gene/Pathway(薬物標的遺伝子/パスウェイリスト)
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * | KEGG DRUG * | DrugBank | 指定難病告示番号 * |
1 | Adipocytokine signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
2 | African trypanosomiasis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
3 | AGE-RAGE signaling pathway in diabetic complications |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
4 | Allograft rejection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
5 | Alzheimer disease |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
6 | Amoebiasis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
7 | Amphetamine addiction |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
8 | Amyotrophic lateral sclerosis (ALS) |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
9 | Antifolate resistance |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
10 | Antigen processing and presentation |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
11 | Apoptosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
12 | Asthma |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
13 | Axon guidance |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
14 | B cell receptor signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
15 | C-type lectin receptor signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
16 | Calcium signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
17 | Cellular senescence |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
18 | cGMP-PKG signaling pathway |
1件: OPRD1 | D02095 | Naltrexone | 11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
D05113 | |||||
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 | ||
19 | Chagas disease (American trypanosomiasis) |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
20 | Cytokine-cytokine receptor interaction |
1件: CSF3R | D03235 | Filgrastim | 28件: 2, 6, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 85, 96, 113, 164, 283, 284, 285, 331 |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 | ||
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
21 | Dilated cardiomyopathy (DCM) |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
22 | DNA replication |
2件: POLA1, POLA2 | D03546 | Clofarabine | 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 |
23 | Dopaminergic synapse |
3件: PPP3CA, PPP3CB, PPP3CC | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
24 | Drug metabolism - other enzymes |
1件: RRM1 | D03546 | Clofarabine | 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 |
25 | EGFR tyrosine kinase inhibitor resistance |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
26 | Epstein-Barr virus infection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
27 | Estrogen signaling pathway |
1件: OPRM1 | D02095 | Naltrexone | 11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
D05113 | |||||
28 | Fc epsilon RI signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
29 | Fluid shear stress and atherosclerosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
30 | Glucagon signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
31 | Glutamatergic synapse |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
32 | Glutathione metabolism |
1件: RRM1 | D03546 | Clofarabine | 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 |
33 | Graft-versus-host disease |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
34 | Hematopoietic cell lineage |
1件: CSF3R | D03235 | Filgrastim | 28件: 2, 6, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 85, 96, 113, 164, 283, 284, 285, 331 |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 | ||
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
35 | Hepatitis B |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
36 | Hepatitis C |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
37 | Herpes simplex virus 1 infection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
38 | HIF-1 signaling pathway |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
39 | Human cytomegalovirus infection |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 | ||
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
40 | Human immunodeficiency virus 1 infection |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
41 | Human papillomavirus infection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
42 | Human T-cell leukemia virus 1 infection |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
43 | Hypertrophic cardiomyopathy (HCM) |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
44 | IL-17 signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
45 | Inflammatory bowel disease (IBD) |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
46 | Influenza A |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
47 | Insulin resistance |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
48 | JAK-STAT signaling pathway |
1件: CSF3R | D03235 | Filgrastim | 28件: 2, 6, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 85, 96, 113, 164, 283, 284, 285, 331 |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 | ||
49 | Kaposi sarcoma-associated herpesvirus infection |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
50 | Legionellosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
51 | Leishmaniasis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
52 | Long-term potentiation |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
53 | Malaria |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
54 | MAPK signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
55 | Metabolic pathways |
1件: DHODH | D00749 | Leflunomide | 10件: 11, 40, 46, 49, 53, 66, 162, 224, 271, 300 |
1件: RRM1 | D03546 | Clofarabine | 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 | ||
56 | Morphine addiction |
1件: OPRM1 | D02095 | Naltrexone | 11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
D05113 | |||||
57 | mTOR signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
58 | Natural killer cell mediated cytotoxicity |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
59 | Necroptosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
60 | Neuroactive ligand-receptor interaction |
1件: NR3C1 | D00407 | Methylprednisolone | 36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
D00751 | |||||
D00979 | |||||
D05000 | |||||
D05001 | |||||
D05002 | |||||
D00473 | Prednisone | 44件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 145, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 | |||
D08416 | Prednisone acetate | 6件: 35, 40, 41, 49, 162, 224 | |||
D00385 | Triamcinolone | 18件: 6, 10, 13, 35, 40, 41, 42, 43, 44, 45, 46, 56, 70, 90, 96, 97, 226, 298 | |||
D00983 | |||||
D00984 | |||||
D00985 | |||||
D06216 | |||||
3件: OPRD1, OPRK1, OPRM1 | D02095 | Naltrexone | 11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 | ||
D05113 | |||||
61 | NF-kappa B signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
62 | NOD-like receptor signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
63 | Non-alcoholic fatty liver disease (NAFLD) |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
64 | Oocyte meiosis |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
65 | Osteoclast differentiation |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
66 | Oxytocin signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
67 | Pathogenic Escherichia coli infection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
68 | Pathways in cancer |
1件: CSF3R | D03235 | Filgrastim | 28件: 2, 6, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 85, 96, 113, 164, 283, 284, 285, 331 |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 | ||
69 | PD-L1 expression and PD-1 checkpoint pathway in cancer |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
70 | Pertussis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
71 | PI3K-Akt signaling pathway |
1件: CSF3R | D03235 | Filgrastim | 28件: 2, 6, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 85, 96, 113, 164, 283, 284, 285, 331 |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 | ||
72 | Proteoglycans in cancer |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
73 | Purine metabolism |
1件: RRM1 | D03546 | Clofarabine | 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 |
74 | Pyrimidine metabolism |
1件: DHODH | D00749 | Leflunomide | 10件: 11, 40, 46, 49, 53, 66, 162, 224, 271, 300 |
1件: RRM1 | D03546 | Clofarabine | 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 | ||
75 | Renin secretion |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
76 | Rheumatoid arthritis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
77 | RIG-I-like receptor signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
78 | Shigellosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
79 | Sphingolipid signaling pathway |
1件: OPRD1 | D02095 | Naltrexone | 11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
D05113 | |||||
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
80 | Systemic lupus erythematosus |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
81 | T cell receptor signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
82 | TGF-beta signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
83 | Th1 and Th2 cell differentiation |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
84 | Th17 cell differentiation |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 | ||
85 | TNF signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
86 | Toll-like receptor signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
87 | Toxoplasmosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
88 | Tuberculosis |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
89 | Type I diabetes mellitus |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
90 | Type II diabetes mellitus |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
91 | VEGF signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
92 | Viral protein interaction with cytokine and cytokine receptor |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
93 | Wnt signaling pathway |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 | D00184 | Ciclosporin | 44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
94 | Yersinia infection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |